ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Indian generics producer Dr. Reddy's Laboratories will abandon its proprietary drug discovery efforts but will remain active in drug development. The firm will transfer its drug discovery staff and facilities in Hyderabad to its contract research subsidiary Aurigene. As part of the reorganization, Dr. Reddy's will close an R&D lab in Atlanta. The firm says it will still conduct drug development work by licensing promising drug candidates from Aurigene and others.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter